What Happened

CVS Pharmacy Inc., a Rhode Island-based pharmacy chain, and its related corporate entities agreed on October 13, 2026 to pay $315 million to resolve allegations that they illegally filled prescriptions for opioids and other controlled substances and then sought payment for many of them from Medicare and other federal healthcare programs.

According to the U.S. Department of Justice, the settlement covers the period from October 17, 2013 through December 2, 2025 and resolves alleged violations of the Controlled Substances Act and the False Claims Act. The government's complaint, filed December 13, 2024 in the U.S. District Court for the District of Rhode Island, alleged that CVS knowingly filled prescriptions that lacked a legitimate medical purpose, were not valid, or were not issued in the usual course of professional practice.

The settlement resolves allegations only; the release does not state a determination of liability. The case began as a qui tam (whistleblower) suit filed by Hillary Estright, a former CVS employee, under the False Claims Act, and the United States intervened. The amount the whistleblower will receive has not yet been determined.

What Was Alleged

  • Dangerous and excessive opioid quantities and opioid prescriptions filled too early.
  • "Trinity" prescriptions — a dangerous and abused combination of an opioid, a benzodiazepine and a muscle relaxant.
  • Prescriptions from "pill mill" prescribers who issued large numbers of controlled substance prescriptions without any medical purpose.
  • Red flags that were not acted on — the government alleged CVS pharmacists filled these prescriptions despite clear red flags that they likely lacked a legitimate medical purpose.
  • Corporate pressure — the complaint alleged that performance metrics, incentive compensation and staffing policies prioritized profit over patient safety, that CVS did not employ enough pharmacists, and that its policies prevented pharmacists from warning one another about certain problematic prescribers.

Settlement Terms

In addition to the $315 million payment, CVS entered into a memorandum of agreement with the DEA covering its future obligations in dispensing controlled substances. It requires CVS to:

  • establish a hotline for both employees and the public to report suspected illegal dispensing of controlled substances;
  • proactively monitor the dispensing patterns of its pharmacies to identify and address potentially illegal dispensing; and
  • establish a process to evaluate prescribers suspected of illegal prescribing.

Lessons for Pharmacies

This case concerns dispensing, not employee theft, but the control themes overlap with a diversion program. The remedial terms above point to the safeguards the government expects to see:

  • A way for staff to report suspected illegal dispensing, and a way for pharmacists to share concerns about a prescriber.
  • Routine review of dispensing patterns, including quantity, early-fill and combination-therapy red flags.
  • A documented process for evaluating prescribers who raise concerns.
  • Staffing and productivity targets that leave pharmacists time to resolve red flags before filling.

Related Guidance

Sources